Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Clarification Of Health Claims "Scientific Agreement" Standard Ordered

This article was originally published in The Tan Sheet

Executive Summary

Clarification by FDA of the "significant scientific agreement" standard it uses to evaluate health claims for dietary supplements was ordered by a federal appeals court in a Jan. 15 decision.

Related Content

FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court
FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge
Nutraceutical Research & Education Act Introduced By Rep. Pallone Oct. 1
FDA Revised Strategy Toward Health Claims Requested By Pearson Plaintiffs
Dietary Supplement Health Claims Data Requested By FDA
Disclaimers May Be "Subterfuge" For Disease Claims, PhRMA Exec Warns
FDA Immediate Approval Of Pearson Health Claims Sought By Legislators
GMP Identity Test Exemption For Small Ingredient Batches Suggested To FDA
Significant Scientific Agreement Standard Should Be "Flexible," Cmte. Says
Pearson v. Shalala





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts